TE Tirzepatide Editorial

Provider review

Mochi Health Tirzepatide Review

Released: · Last reviewed:

Direct answer

Mochi Health is reviewed here against a fixed evidence checklist: advertised and all-in tirzepatide pricing, mandatory fees, dose coverage, pharmacy, clinician model and cancellation terms. Mochi Health prints $90–$199 a month for medication by dose, plus a $199/12-month membership (read on its own page on October 15, 2026). It is listed but not compared like-for-like: Priced per dose, so there is no single monthly figure; all-in runs about $106.58 at the lowest dose to $215.58 at 16.6 mg.

Key takeaways

  • Printed figure $90–$199 a month for medication by dose, plus a $199/12-month membership; not a standing all-in price (Priced per dose, so there is no single monthly figure; all-in runs about $106.58 at the lowest dose to $215.58 at 16.6 mg).
  • Mandatory fees: Separate membership: $199 for 12 months, shown as $17/mo (read October 15, 2026).
  • Compounding pharmacy, licence, facility type, clinicians, states, and cancellation terms are all unverified and shown as Verification Pending rather than inferred.
  • Compounded tirzepatide is not FDA approved and is not reviewed by the FDA before sale.
Current regulatory status — compounded tirzepatide. The FDA determined the tirzepatide shortage resolved on 2 October 2024 and reaffirmed it by declaratory order on 19 December 2024. Enforcement discretion for compounding ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities, and a federal court upheld the determination in May 2025. Federal law prohibits compounding a copy of a commercially available approved drug outside a shortage, so routine compounded tirzepatide is no longer permitted. Telehealth programs still sell compounded tirzepatide prepared for individual patients by state-licensed 503A pharmacies; FDA's September 18, 2026 warning letter to Empower Pharmacy (738238) said compounded tirzepatide and semaglutide products it reviewed “appear to be essentially copies” of the approved drugs. Prices on this site are dated first-party reads, not a finding that any product is lawful. Full timeline and sources.
Mochi Health — verification checklist
ProviderMochi Health
Operating statusActive
Program typeCompounded-GLP-1-focused
Tirzepatide price (as captured)$90–$199 a month for medication by dose, plus a $199/12-month membership (read 2026-10-15)
Normalised monthly costNot comparable: Priced per dose, so there is no single monthly figure; all-in runs about $106.58 at the lowest dose to $215.58 at 16.6 mg.
Mandatory feesSeparate membership: $199 for 12 months, shown as $17/mo (read October 15, 2026)
Medication includedMedication price separate from membership
Billing cadenceMonthly
Compounding pharmacyVerification Pending
Pharmacy licenceVerification Pending
Facility type (503A/503B)Verification Pending
Named cliniciansVerification Pending
States servedVerification Pending
Dose coverageVerification Pending
Shipping termsVerification Pending
Cancellation policyVerification Pending
Refund policyVerification Pending
Auto-renewal termsVerification Pending
Evidence sourceOfficial provider
Source confidenceHigh
Price verified2026-10-15
Partially verified
Medical reviewers Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Released 2026-07-22
Updated
Price verified 2026-10-15
Methodology v4.1

What is the verdict on this provider?

Mochi Health prints a price, but not one this site can compare like-for-like: Priced per dose, so there is no single monthly figure; all-in runs about $106.58 at the lowest dose to $215.58 at 16.6 mg. That is a comparability limitation, not a judgement about the service.

What does tirzepatide actually cost at Mochi Health?

Mochi Health prints $90–$199 a month for medication by dose, plus a $199/12-month membership (read on its own page on October 15, 2026). It is listed but not compared like-for-like: Priced per dose, so there is no single monthly figure; all-in runs about $106.58 at the lowest dose to $215.58 at 16.6 mg.

Source: joinmochi.com. Confirm the recurring price after any first month, every mandatory fee and the price at your maintenance dose at checkout before enrolling.

What does the captured source actually state?

Mochi Health — verbatim captured evidence, 2026-07-20
FieldText as captured from the provider's own page
Tirzepatide pricing, as publishedMedication $199/month + membership $79/month after introductory month = about $278/month ongoing
Semaglutide pricing, as publishedMedication $99/month + membership $79/month after introductory month = about $178/month ongoing
Fee structure, as publishedMembership $39 first month, then $79/month; shipping advertised included
Medication inclusion, as publishedMedication price separate from membership
Billing cadence, as publishedMonthly
Evidence typeCurrent advertised component pricing
Capture caveatEffective total assumes standard recurring membership and excludes optional extras.

How should the Mochi Health pricing structure be read?

Mochi Health publishes a monthly billing cadence in the captured source. Month-to-month billing generally costs more per month than a committed tier but leaves less money at risk if treatment is stopped early, which matters most before tolerance is established.

The same source also publishes semaglutide pricing, which is useful context: a provider pricing both drugs allows a switch without changing provider, though the two are not interchangeable and any change is a prescriber decision.

Source confidence is recorded as high because the figures come from Official provider rather than secondary reporting. That describes the capture, not how long it will remain accurate — pricing in this market changes frequently.

What has not been verified?

Verification Pending. Not verified first-party for Mochi Health, and therefore not asserted: the compounding pharmacy identity and state licence, 503A versus 503B facility type, named prescribing clinicians, states served, dose coverage at higher doses, shipping terms, cancellation and refund policy, and auto-renewal terms. Publishing an inferred pharmacy name or an assumed cancellation policy would give a false impression of verification, so these fields stay blank until a checkout capture and licence lookup are completed.

What should you confirm before enrolling?

  • The recurring price after any introductory or first-month rate, in writing.
  • Every mandatory fee: membership, consultation, shipping, and any dose-related surcharge.
  • Which compounding pharmacy dispenses, its state licence number, and whether it is 503A or 503B.
  • What happens to the price when your dose increases.
  • The cancellation method, notice period, and whether prepaid months are refundable.
  • Whether the plan auto-renews and how to stop it.
  • That a licensed clinician reviews your intake and is reachable for side-effect questions.

What are the alternatives?

Primary source: Mochi Health pricing page · captured 2026-07-20. Effective total assumes standard recurring membership and excludes optional extras.

What is Mochi Health's status after the compounding change?

Mochi Health was captured on 2026-07-20 advertising compounded tirzepatide. That capture predates nothing — it is recent — but the legal basis for the product it describes changed before it was taken. Compounding of tirzepatide was permitted only while the drug sat on the FDA shortage list. The shortage was declared resolved on 2 October 2024 and reaffirmed by declaratory order on 19 December 2024, and enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities.

This site records Mochi Health's prices with the date each was read and compares them only on a like-for-like basis (see the position table). If Mochi Health continues to advertise compounded tirzepatide, the useful question is not whether the price is competitive but what legal basis the product is supplied under and which state-licensed pharmacy dispenses it. Neither is verified in this record.

Post-shortage position for Mochi Health, as far as the evidence supports
QuestionPosition for Mochi HealthHow this site treats it
Was compounded tirzepatide advertised at capture?YesRecorded with its read date
Operating status at captureActiveReported as captured; not re-verified since
Legal basis for continued compounded supplyNot disclosed in the captured sourceVerification Pending — not inferred
Dispensing pharmacy identityNot disclosedVerification Pending
Whether approved products are now offeredNot established in this recordVerification Pending — ask the provider directly
Why this page keeps older captures. Earlier prices stay visible with their dates so readers can compare what they were charged with what was advertised. Current figures are in the notice, checklist and position table above.

How does Mochi Health compare with the other programs in our index?

Mochi Health is listed in our index with the figure it prints ($90–$199 a month for medication by dose, plus a $199/12-month membership) but is not placed in the standing-price order: Priced per dose, so there is no single monthly figure; all-in runs about $106.58 at the lowest dose to $215.58 at 16.6 mg. For reference, the 15 programs with standing all-in prices cost $1,368 to $3,640 for twelve months on their cheapest plans (median $2,568).

The standing-price index, for context (sorted low to high by twelve-month cost, November 8, 2026)
#ProgramLowest monthlyPlan behind itMonth to month12-month costHow the 12 months are boughtSource · read
1Mondae$114$114/mo on a prepaid 6-month plan ($684)$126$1,368two 6-month plans at $684mondae.com · 2026-10-15
2NexLife$115$115/mo on a 12-month plan ($1,380)$129$1,38012-month plannexlife.us · 2026-11-06
3TRYM Health$125$125/mo on the 12-month plan ($1,500 one-time payment)$180$1,50012-month one-time paymenttrymhealth.com · 2026-11-08
4Eden$129$129 every month$129$1,54812 × $129eden.health · 2026-10-15
5Sprout Health$149$149/mo on the 12-month plan ($1,788 up front)$199/4 wk$1,78812-month plan billed up frontjoinsprouthealth.com · 2026-10-15
6He & She MD$159$159/mo on the 12-month plan$339$1,90812 × $159heandshemd.com · 2026-10-15
7Bodybuilding Health+$174.67$174.67/mo on 6 months$209$2,096two 6-month plansbbhealthplus.com · 2026-10-15
8TelePep$214$214/mo on the annual plan ($2,568 up front)$249$2,568annual plan up fronttelepeptide.org · 2026-10-15
9Yucca Health$225$225/mo on 6 months ($1,350)$258$2,700two 6-month planstryyucca.com · 2026-09-04 (carried)
10Join Josie$233.25$233.25/mo on 12 months ($2,799)$349$2,79912-month planjoinjosie.com · 2026-10-15
11Pallas Health$239$239/mo average on the annual plan$299/4 wk$2,86812 × $239 averagepallashealth.co · 2026-10-15
12Fridays$240$240/mo on the annual plan (paid annually)$359$2,88012 × $240joinfridays.com · 2026-10-15
13Found$239$239 per 4 weeks on the 12-month cash plan$359/4 wk$3,10713 cycles × $239joinfound.com · 2026-10-15
14Zappy Health$299$299/mo on 6 months ($1,794)$349$3,588two 6-month planszappyhealth.com · 2026-11-08
15Enhance.MD$280$280 per 4 weeks on the 12-month plan$329/4 wk$3,64013 cycles × $280enhance.md · 2026-10-15

What else does Mochi Health's captured record contain?

The full record held for Mochi Health is reproduced below. This site publishes the underlying capture rather than only its own summary, so a reader can see exactly what the interpretation rests on and disagree with it if the reading looks wrong.

Complete captured record for Mochi Health
FieldValue held for this provider
Programme categoryCompounded-GLP-1-focused
Operating statusActive
Tirzepatide pricing, as capturedMedication $199/month + membership $79/month after introductory month = about $278/month ongoing
Semaglutide pricing, as capturedMedication $99/month + membership $79/month after introductory month = about $178/month ongoing
Mandatory fees, as capturedMembership $39 first month, then $79/month; shipping advertised included
Medication inclusionMedication price separate from membership
Billing cadenceMonthly
Evidence typeCurrent advertised component pricing
Capture caveatsEffective total assumes standard recurring membership and excludes optional extras.
SourceOfficial provider
Source confidenceHigh
Price verified2026-07-20

Mochi Health's semaglutide pricing is recorded because the relationship between a provider's semaglutide and tirzepatide pricing is informative on its own. Semaglutide is typically the cheaper of the two in this market, and a provider whose tirzepatide premium is unusually large or unusually small relative to its semaglutide rate is worth asking about — it can reflect different pharmacy sourcing, different dose coverage, or a promotional structure that will not persist. For Mochi Health the captured semaglutide text reads: Medication $99/month + membership $79/month after introductory month = about $178/month ongoing

The capture for Mochi Health is rated high confidence, meaning the figures were stated plainly on a first-party page in a form that left little room for interpretation. High confidence concerns the accuracy of the transcription, not the durability of the price: providers in this market change pricing frequently, and the verification date above is the honest boundary on how much weight the figure should carry.

What should you ask Mochi Health before enrolling?

These questions are selected against the specific gaps in Mochi Health's record rather than being a generic checklist. Ask them in writing and keep the reply: a verbal assurance from a sales channel is not a contractual term, and terms are what govern a dispute.

  • What is the recurring monthly price after any introductory or first-month rate?
  • Is the medication itself included in that price, or billed separately?
  • What recurring fees apply on top of the medication, and are any of them waived initially?
  • Which compounding pharmacy prepares the medication, and what is its state licence number?
  • Is that pharmacy a 503A compounder or a 503B outsourcing facility?
  • Does the price change when the dose increases to 10 mg or 15 mg?
  • What concentration is dispensed, in mg/mL, and what beyond-use date is assigned?
  • How is the plan cancelled, what notice is required, and are prepaid months refundable?
  • Does the plan auto-renew, and how is renewal stopped?
  • Which licensed clinician reviews the intake, and how are side-effect questions handled?

A provider that answers all of these in writing has demonstrated something meaningful about how it operates. A provider that will not name its compounding pharmacy before payment has also told you something, and it is worth weighing that refusal as evidence in its own right.

What should you ask Mochi Health now?

These questions are written for the post-shortage position rather than for a price comparison. The first three matter most: a provider still advertising compounded tirzepatide should be able to explain its legal basis and name its pharmacy, and an inability to do either is the most informative answer available.

  • Is Mochi Health still supplying tirzepatide, and if so in what form?
  • If a compounded product is still offered, what is the legal basis for supplying it?
  • Which state-licensed pharmacy dispenses, and what is its licence number?
  • Is the pharmacy a 503A compounder or a 503B outsourcing facility?
  • Does the programme now offer FDA-approved Zepbound or Mounjaro instead?
  • If an approved product is offered, is the price the medication alone or medication plus programme fees?
  • Will the programme support an insurance prior-authorisation or appeal on your behalf?
  • What happens to any prepaid balance if the programme can no longer supply what you paid for?
  • How is cancellation handled, what notice is required, and are unused months refunded?
  • Which licensed clinician is responsible for your care, and how are they contacted?

Prepaid balances deserve particular attention. Anyone who prepaid a multi-month compounded programme before the enforcement deadlines has a reasonable question about what they were supplied afterwards, and that question is worth putting in writing.

What do the technical terms on this page mean?

Definitions for the 10 technical terms this page uses, including 503A, 503B, GLP-1, auto-renewal — in the specific sense used above.

Terms used on this page
503AA pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility.
503BAn outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval.
GLP-1Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion.
auto-renewalA term under which a plan renews automatically unless cancelled. Combined with a notice period, it determines how much money is at risk if treatment stops.
beyond-use dateThe date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing.
compoundedPrepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial.
effective monthly costThe recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking.
membership feeA recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper.
mg/mLMilligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations.
subcutaneousBeneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm.

Frequently asked questions

How much does tirzepatide cost at Mochi Health?

Mochi Health prints $90–$199 a month for medication by dose, plus a $199/12-month membership (read on its own page on October 15, 2026). It is listed but not compared like-for-like: Priced per dose, so there is no single monthly figure; all-in runs about $106.58 at the lowest dose to $215.58 at 16.6 mg. Confirm the recurring price and every mandatory fee at checkout before enrolling.

Which pharmacy does Mochi Health use?

Not verified. The compounding pharmacy identity, its state licence, and whether it is a 503A or 503B facility have not been confirmed first-party, so nothing is asserted.

Is Mochi Health cheaper than other providers?

Its printed figure ($90–$199 a month for medication by dose, plus a $199/12-month membership) is not a standing all-in price, so this site does not place it in the order: Priced per dose, so there is no single monthly figure; all-in runs about $106.58 at the lowest dose to $215.58 at 16.6 mg. Ask for the recurring price at a maintenance dose and compare it with our index, where standing plans cost $1,368 to $3,640 for twelve months.

Is compounded tirzepatide FDA approved?

No. Compounded tirzepatide is not FDA approved and is not reviewed by the FDA for safety, effectiveness, or quality before sale.

Sources for this page

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Change history

Substantive changes to this page
DateChange
2026-07-22Page published with current dataset snapshot.
2026-09-04Ranked set and category median rebuilt from the 2026-09-04 dataset (7 of 29 records ranked; NexLife re-read live, Yucca Health and a program since removed from this site added). Relationship disclosure updated: NexLife is a disclosed commercial partner of the publisher; this provider's own record is unchanged.
2026-11-08Price record updated to the October 15, 2026 read; checklist, verdict, cost section, position table and FAQ answers rebuilt; dated notice added above the older capture.

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.

What else is in this section?